Hikma Pharmaceuticals has been demoted from the UK’s premier stock market index. Effective from the start of trading on Monday, March 23, the company is now a constituent of the FTSE 250, having exited the flagship FTSE 100. This shift reflects a period of significant share price decline and triggers mandatory portfolio adjustments for funds that track these indices.
Market Pressure from Index Funds
The reclassification by FTSE Russell has immediate technical consequences. Index-tracking exchange-traded funds (ETFs) and other passive vehicles that mirror the FTSE 100 are compelled to sell their holdings in Hikma. This selling pressure is a key factor behind the stock’s elevated volatility, which currently stands above 54%. While membership in the FTSE 100 guarantees substantial liquidity, the move to the mid-cap index often introduces near-term downward pressure on a stock’s price.
The demotion follows a challenging period for the company’s equity value. Since the beginning of the year, Hikma shares have declined by approximately 17.5%. Trading at a current price of €14.60, the stock remains well below its 52-week high of €21.40. Markets showed tentative signs of absorbing the index-related selling on Monday, however, with the shares closing up by nearly 0.7%.
Should investors sell immediately? Or is it worth buying Hikma?
Strategic Roadmap Under Scrutiny
Investor focus is now turning to the company’s operational strategy and future prospects. Hikma recently published its 2025 annual report and issued the notice for its 2026 Annual General Meeting (AGM) on March 18. These documents outline the strategic framework management intends to use to rebuild investor confidence.
The upcoming AGM represents a critical event where executives are expected to provide detailed plans for growth as a FTSE 250 entity. A central question for shareholders is whether the company can establish a firm foundation within the mid-cap index, potentially setting the stage for a future return to the FTSE 100.
Ad
Hikma Stock: Buy or Sell?! New Hikma Analysis from November 8 delivers the answer:
The latest Hikma figures speak for themselves: Urgent action needed for Hikma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.
Hikma: Buy or sell? Read more here...
